Poxel/Sumitomo's Novel Diabetes Therapy Imeglimin Nears Japan Market
A Phase III-Ready Partnering Opportunity For EU/US
Executive Summary
Poxel’s potential first-in-class diabetes therapy, imeglimin, could be approved in Japan this year, and a new partner is being sought for the EU and US – events that would transform the outlook for the decade-old Merck Serono spin-out.
You may also be interested in...
Poxel’s Pioglitazone Formulation Meets Key Endpoints In Phase II NASH Study
A version of the diabetes drug intended to reduce PPAR gamma activation shows hoped for benefits and safety in a Phase II study. Poxel will now choose to advance one of two mid-stage NASH candidates.
Stock Watch: Poxel Passes Go…But To Where?
Poxel’s shift to new therapeutic areas may be necessary despite Japan’s approval for its diabetes drug. Twymeeg looks set to be hamstrung by placebo-controlled studies without outcomes data.
Latest Japan Approvals Include Evrysdi For SMA
Japan's latest batch of product approvals includes the country's second therapy for SMA and the first nod globally for a novel antidiabetic.